Nephros (STU:NPJP) Cyclically Adjusted Revenue per Share: €1.11 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:NPJP Nephros Inc STU:NPJP
60 GF Score
Price €3.50
GF Value €2.79
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Nephros Cyclically Adjusted Revenue per Share?

Nephros STU:NPJP -7.41% 60 Cyclically Adjusted Revenue per Share is €1.11 as of Jun. 2026. GuruFocus rates STU:NPJP with a GF Score™ of 60/100 and a GF Value™ of €2.79 (Modestly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Nephros's adjusted revenue per share for the three months ended in Jun. 2026 was €0.470. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €1.11 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Nephros's average Cyclically Adjusted Revenue Growth Rate was 14.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 1.30% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -19.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Nephros was 7.60% per year. The lowest was -36.10% per year. And the median was -23.55% per year.

As of today (2026-08-23), Nephros's current stock price is €3.50. Nephros's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €1.11. Nephros's Cyclically Adjusted PS Ratio of today is 3.15.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Nephros was 9.22. The lowest was 0.35. And the median was 1.79.


Nephros  (STU:NPJP) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Nephros's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3.50/1.11
=3.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Nephros was 9.22. The lowest was 0.35. And the median was 1.79.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Nephros Cyclically Adjusted Revenue per Share Related Terms


Nephros Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Nephros's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nephros Cyclically Adjusted Revenue per Share Chart

Nephros Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 1.00 1.00

Nephros Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.94 0.95 1.00 1.08 1.11

STU:NPJP vs MLSS, POCI, HBIO: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, Nephros's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nephros Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nephros's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Nephros's Cyclically Adjusted PS Ratio falls into.


STU:NPJP
60GF Score
Nephros Inc STU:NPJP
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nephros Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nephros's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.47/333.9520*333.9520
=0.470

Current CPI (Jun. 2026) = 333.9520.

Nephros Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.078 241.428 0.108
201612 0.130 241.432 0.180
201703 0.124 243.801 0.170
201706 0.128 244.955 0.175
201709 0.128 246.819 0.173
201712 0.182 246.524 0.247
201803 0.129 249.554 0.173
201806 0.166 251.989 0.220
201809 0.207 252.439 0.274
201812 0.199 251.233 0.265
201903 0.220 254.202 0.289
201906 0.277 256.143 0.361
201909 0.365 256.759 0.475
201912 0.358 256.974 0.465
202003 0.266 258.115 0.344
202006 0.156 257.797 0.202
202009 0.199 260.280 0.255
202012 0.198 260.474 0.254
202103 0.233 264.877 0.294
202106 0.189 271.696 0.232
202109 0.218 274.310 0.265
202112 0.235 278.802 0.281
202203 0.192 287.504 0.223
202206 0.262 296.311 0.295
202209 0.236 296.808 0.266
202212 0.233 296.797 0.262
202303 0.335 301.836 0.371
202306 0.318 305.109 0.348
202309 0.335 307.789 0.363
202312 0.285 306.746 0.310
202403 0.309 312.332 0.330
202406 0.287 314.175 0.305
202409 0.300 315.301 0.318
202412 0.341 315.605 0.361
202503 0.425 319.799 0.444
202506 0.354 322.561 0.367
202509 0.368 324.800 0.378
202512 0.356 324.054 0.367
202603 0.410 330.213 0.415
202606 0.470 333.952 0.470

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €1.11 mean?
Nephros (STU:NPJP) has a Cyclically Adjusted Revenue per Share of €1.11 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Nephros and its competitors.
Is Nephros' Cyclically Adjusted Revenue per Share too high?
Nephros' current Cyclically Adjusted Revenue per Share is €1.11. Overall, Nephros has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nephros' Cyclically Adjusted Revenue per Share compare to MLSS and POCI?
Nephros' Cyclically Adjusted Revenue per Share of €1.11 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Nephros and its competitors. Nephros's current Cyclically Adjusted Revenue per Share is €1.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nephros stock overvalued right now?
Based on GuruFocus' analysis, Nephros (STU:NPJP) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.79, compared to a current price of €3.50 — trading 25.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €1.11. Nephros' overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Nephros (STU:NPJP), the current Cyclically Adjusted Revenue per Share is €1.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nephros (STU:NPJP) Overvalued in 2026?

Based on GuruFocus' analysis, Nephros stock appears to be overvalued. The current stock price of €3.50 is trading 25.4% above its estimated GF Value™ of €2.79. GuruFocus considers Nephros to be Modestly Overvalued.

Key valuation signals for STU:NPJP:

  • Cyclically Adjusted Revenue per Share: €1.11
  • GF Value™: €2.79 vs. price of €3.50 (25.4% above fair value)
  • GF Score™: 60/100 with 3 warning signs

No single metric tells the full story. See the STU:NPJP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nephros Business Description

Other Exchanges NEPH:USA
Address 380 Lackawanna Place, South Orange, NJ, USA, 07079
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.
60GF Score

Get the complete analysis for STU:NPJP

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.50
Price
€2.79
GF Value